Anti-mouse CD3e (Clone: 500A2) | Recombinant, in vivo grade

Catalog No.	Product Name	Size	List Price (US$)
PA007201	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa	1 mg	150.00
PA007201	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa	5 mg	350.00
PA007201	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa	25 mg	900.00

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007201

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa

1 mg

150.00

PA007201

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa

5 mg

350.00

PA007201

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa

25 mg

900.00

Description

PA007201: In vivo Grade Recombinant Anti-mouse CD3e Mouse IgG2a Kappa Monoclonal Antibody (Clone: 500A2)

Recombinant mouse IgG2a Monoclonal Antibody.
Clone: 500A2.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse CD3e monoclonal antibody (clone: 500A2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 500A2) specifically binds to the mouse T cell receptor CD3e.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD3e protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2)

CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells

Xingjie Ren, et al. Front Immunol. 2022 Oct 27;13:1012674. doi: 10.3389/fimmu.2022.1012674. PMID: 36389920; PMCID: PMC9643874

“Selective depletion of T cell subsets remains a major challenge in immunotherapy. This research illustrates that CD3e-targeted immunotoxins can precisely eliminate high-expressing CD3e T cells while leaving regulatory T cells (Tregs) with low CD62L expression unharmed. This targeted strategy provides a highly refined approach for modulating the immune landscape within specific organs.”

(Tags: 500A2; In vivo depletion)

Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage

Shihyoung Kim, et al. Toxins (Basel). 2022 Jun 15;14(6):410. doi: 10.3390/toxins14060410. PMID: 35740248; PMCID: PMC9220018

“Targeted therapies involving anti-CD3e antibodies and their derived immunotoxins are significant tools for T-cell disorder management. A common complication with these treatments is vascular leak syndrome, which presents safety concerns in clinical applications. This study confirms that the sZAP component of the immunotoxin, rather than the antibody moiety itself, is the primary mediator of vascular toxicity in mouse models.”

(Tags: Anti-mouse CD3e; T cell activation)

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

Andrea Cossarizza, et al. Eur J Immunol. 2024 May;54(5):e50529. doi: 10.1002/eji.202350529. PMID: 38766904; PMCID: PMC11115438

“Flow cytometry is an essential technology for the analysis and isolation of immune cell populations. These guidelines offer comprehensive recommendations to ensure standardization and high-quality data generation across immunological research. This edition places particular emphasis on technical best practices for surface marker labeling and cellular sorting procedures.”

(Tags: 500A2; Flow cytometry)

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma

Jared M. P. Grier, et al. J Immunother Cancer. 2022 Sep;10(9):e004655. doi: 10.1136/jitc-2022-004655. PMID: 36070923; PMCID: PMC9463572

“Regulatory T cells (Tregs) in the tumor microenvironment frequently inhibit effective anti-tumor immune responses. The authors demonstrate that cyclophosphamide treatment significantly reduces tumor-infiltrating Treg populations, thereby enhancing the efficacy of subsequent immune checkpoint blockade. The combination of chemotherapy and anti-PD-1 therapy leads to improved survival outcomes in a murine model of neuroblastoma.”

(Tags: Mouse CD3 epsilon; TCR signaling)

The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

Sarah E. Marsh, et al. J Exp Med. 2016 Mar 7;213(3):363-75. doi: 10.1084/jem.20150937. PMID: 26903612; PMCID: PMC4780638

“The role of adaptive immunity in neurodegenerative conditions like Alzheimer’s disease has been a subject of intense investigation. This research demonstrates that the adaptive immune system plays a protective role by influencing the behavior and activation state of microglia. Modulation of this immune interaction offers a potential therapeutic avenue to restrain disease pathogenesis in the brain.”

(Tags: Anti-mouse CD3; Syrian hamster IgG)